Table 1. Selected FGFR inhibitors currently used in clinical development and/or evaluation.
| DRUG | Company | TARGETS | Clinical development stage |
|---|---|---|---|
| Small-Molecule TKIs | |||
| Vargalef (BIBF1120) | Boehringer Ingelheim, Novartis | FGFRs, VEGFR and PDGFR | III |
| Ponatinib (AP24534) | Ariad | FGFR, VEGFR and IGF-1R | I |
| Dovotinib (TKI258) | Novartis | FGFRs, VEGFRs, KIT, FLT3, CSFR and PDGFRs | III |
| Brivanib (BMS582664) | Bristol Myers Squib | VEGFRs and FGFRs | II |
| AZD4547 | Astra Zeneca | FGFRs | I/II |
| Cediranib (AZ2171) | Astra Zeneca | VEGFRs, FGFRs and KIT | III |
| TSU68 (SU668) | Taiho Pahrmace | FGFRs, VEGFR and PDGFR | II |
| E7080 | Eisai | FGFRs, VEGFR and PDGFR | II |
| E3810 | Ethical Oncology Science | FGFRs, VEGFR | I |
| BGJ398 | Novartis | FGFRs | I |
| RG1507 | Roche, Genmab | FGFRs, VEGFR and PDGFR | II |
| LY2874455 | Lilly | FGFRs | n/a |
| FGFR antibodies | |||
| Figitumumab | Pfizer | FGFR, VEGFR and IGF-1R | III |
| Cixutumumab | ImClone Systems | FGFR, VEGFR and IGF-1R | II |
| AMG479 | Amgen | FGFR, VEGFR and IGF-1R | II/III |
| BIIB022 | Biogen Idec | FGFR, VEGFR and IGF-1R | I/II |
| FP1039 (Fusion protein) | Five Prime | FGFR1 | I/II |
| R3Mab | Genectech | FGFR3 | n/a |
Abbreviations: FGFRs, fibroblast growth factor receptors; VEGFRs, vascular endothelial growth factor receptor; PDFRs, platelet derived growth factor receptor; IGF-1R, Insulin Growth factor-1 receptor; KIT, mast/stem cell growth factor receptor; FLT3, fms-like tyrosine Kinase receptor 3; CSFR, colony stimulating factor receptor; n/a, not applicable